The human large tumor suppressor 2 (LATS2/KPM) gene, which encodes a novel serine/threonine kinase, has been mapped onto chromosome 13q11-12, a hot spot region for loss of heterozygosity in primary cancers, suggesting that LATS2 might function as a tumor suppressor gene. 1 Although chromosome aberrations involving 13q12 have been described in a minority (3-6%) of acute lymphoblastic leukemia (ALL) patients and frequently occur as secondary events after relapse, these patients show an extremely poor outcome. 2 DNA methylation is an essential mechanism for the regulation of gene expression in mammalian cells. The promoter of the LATS2 gene contains a defined CpG island and its hypermethylation has been recently associated to an aggressive phenotype in breast cancers. 3 All these facts led us to analyze the potential role of the inappropriate expression/ promoter hypermethylation of the LATS2 gene in a number of cell lines and primary cells from ALL patients.
Four human precursor-B (MY, TOM-1, NALM-20 and TANOUE) and three T cell (JURKAT, LOUCY and MOLT-4) ALL cell lines . DNA from mononuclear marrow cells (n ¼ 20) from healthy donors were used as negative controls for methylation-specific assays.
RNA from mononuclear marrow cells was used for quantitative real-time PCR (qrt-PCR) for LATS2 mRNA expression. Reverse transcription was performed on 1 mg total RNA with random hexamers as reaction primer. Qrt-PCR was performed in a rapid fluorescent thermal cycler (LightCycler2.0, Roche). Primer set was specific for the LATS2 gene (GeneBank: NM_014572; forward LATS2 exon 5, 5
0 -GTAGGACGCAAACG AAT-3 0 ; reverse LATS2 exon 7, 5 0 -CAGAAGTGAACCGGCA-3 0 ). Amplification of Abelson (ABL1) gene transcripts was performed to assess RNA integrity and as reference gene. In order to reduce the variation between different assays and samples, a procedure based on the relative quantification of target genes vs their controls in relation to the reference gene was used. Calculations were automatically performed by LightCycler software (RealQuant, version 1.0, Roche). The selected control was the mononuclear cells of bone marrow specimen from a healthy donor. It was considered as 100% expression.
To determine the cutoff point for altered LATS2 expression in ALL patients and cell lines, the value for LATS2 was firstly determined in 15 bone marrow samples from healthy donors. In these individuals, LATS2 expression fell between 149 and 78% (mean: 104721%). A LATS2 value equal or below 40% (determined as the mean minor 3 s.d.) was chosen to define underexpression of LATS2 in ALL mRNA samples. We found a strong reduction of LATS2 mRNA in all the B/T-cell precursor ALL cell lines tested (mean, 1.4%; range, 0-6%) and also in 35% of diagnostic ALL samples (mean, 15.7%; range, 0-40%).
CpG island of the LATS2 promoter was revealed to be highly methylated in five ALL cell lines lacking LATS2 expression (TOM-1, NALM-20, MY, TANOUE and LOUCY), whereas JURKAT and MOLT-4 cell lines showed an unmethylated pattern despite expressing low LATS2 transcript levels ( Figure 1a ). Exposure to 4 mM concentration of the demethylating agent 5-Aza-2 0 -deoxycytidine restored the expression of LATS2 mRNA in the MY, NALM-20, TOM-1, TANOUE and LOUCY ALL cell lines indicating that hypermethylation is a major mechanism by which LATS2 expression is silenced in ALL cells (Figure 1b) .
LATS2 methylation status was also studied in 66 ALL patients enrolled in this study in which DNA samples were available. A methylated promoter was observed in 16 of them (24%) and in 13 of these cases (81.2%), methylation was associated with decreased LATS2 expression levels. In contrast, low expression was detected in only 11 (8 B-ALL and 3 T-ALL) of 50 ALL with unmethylated pattern (22%). This result indicated that CpG methylation within LATS2 promoter strongly correlated with decreased constitutive expression of LATS2 in ALL cells (Po0.001).
Low expression of LATS2 was detected at diagnosis in 35% (35 out of 101) of ALL patients with adult or childhood ALL belonging to all the FAB subtypes. Reduced levels of LATS2 mRNA were more frequently observed among adult ALL patients (22 out of 47, 47%) than in children (13 out of 54, 24%) (P ¼ 0.01). Moreover, correlating LATS2 expression with pretreatment risk groups, we detected a significant association between reduced LATS2 expression and high-risk ALL children assessed by the NCI scoring system (P ¼ 0.004) and also with two poor-risk subgroups defined by the presence of BCR-ABL fusion gene (P ¼ 0.05) and T-cell lineage ALL (Po0.001). Complete remission (CR) rates of patients with normal and low LATS2 gene expression were 97 and 91%, respectively, suggesting that expression of the LATS2 gene did not correlate with response to remission induction therapy.
As show in Table 1 patients with low expression had higher relapse (53 vs 12%, Po0.001) and mortality (69 vs 14%, Po0.001) rates than normal expressing patients. The adverse prognostic impact of low LATS-2 expression on relapse and mortality remained after adjustment for age, WBC count, immunophenotype, NCI risk groups and cytogenetics. We analyzed the disease-free survival (DFS) and overall survival (OS) according to LATS2 expression. Among children, the 6-year DFS was 80% for normal expressing group and 41.6% for low expressing group (P ¼ 0.0005) (Figure 2a) . Among adult ALL patients, the 2-year DFS was 76% for patients with normal LATS-2 levels and 0% for patients with low LATS-2 levels (Po0.0001) (Figure 2c ). Significant differences were observed in the actuarial OS among patients with normal and low levels of LATS-2 in the separate analyses of children (85.6 vs 36.7%, respectively, P ¼ 0.0003; Figure 2b ) and adults (63.3 vs 0%, respectively, P ¼ 0.0001; Figure 2d) .
A multivariate analysis of potential prognostic factors demonstrated that expression of the LATS2 gene was the most important prognostic factor in predicting DFS (Po0.0001) and OS (Po0.0001) in the global series and also in both childhood (P ¼ 0.002 in DFS and OS) and adult ALL (Po0.0001 in DFS and P ¼ 0.003 in OS). Only factors like BCR-ABL in adults (P ¼ 0.02 in DFS and P ¼ 0.04 in OS) and hyperleucocytosis in children (P ¼ 0.05 in DFS) reached also statistical significance in the multivariate analysis.
In this study we have identified, for the first time, the LATS2 gene as a target gene for epigenetic regulation in ALL. Low expression of LATS2 gene was associated with methylation of the LATS2 promoter region in leukemic cells. Although methylation of the LATS2 promoter was significantly associated with decrease of LATS2 expression, some discordant values were recorded. A minority of patients (n ¼ 3) who expressed normal levels of LATS2 also showed methylation of the gene. All these patients showed levels (42, 48 and 68%) near to the cutoff point (40%) chosen to define underexpression in this study. Although the presence of contaminating RNA from normal bone marrow cells cannot be ruled out in these cases, they also may indicate a partial methylation state of the promoter region. Moreover, our study cannot exclude other potential mechanisms of LATS2 downregulation since in 11 of our ALL patients and also in JURKAT and MOLT-4 cell lines there were no apparent methylation despite loss of LATS2 expression.
What is the functional significance underlying the downregulation of LATS2 in ALL? LATS2 is a putative tumor suppressor gene with three key functions: it negatively regulates the cell cycle by controlling G1-S and/or G2-M transition, 4, 5 induces apoptosis through downregulating antiapoptotic proteins, Bcl-2 and Bcl-x(L), 6 and plays an essential role in the integrity of processes that govern centrosome duplication, maintenance of mitotic fidelity and genomic stability. 7 In this study, decrease of LATS2 expression was found to be correlated with several dismal prognostic features in ALL patients: low expression of LATS2 gene was more frequently observed among classical high-risk ALL groups (adults, T-cell phenotype, NCI poor risk and the presence of BCR-ABL fusion gene) and was also significatively and independently associated with a shorter DFS and OS in both adult and childhood ALL. These findings, together with the general expression of LATS2 in normal bone marrow, the emerging role of the LATS2 gene in other types of human cancer (ie, prostate and breast carcinoma), 3, 8 and the confirmed role for LATS2 gene in mechanisms related to cellular homeostasis, such as apoptosis, genomic integrity and cell cycle regulation are supportive of LATS2 inactivation contributing directly to the clinical behavior of ALL
In conclusion, our results strongly suggest that downregulation of LATS2 expression mainly by aberrant promoter methylation is a frequent event in ALL and plays a role in the clinical outcome of the disease.
